TaiGen releases Taigexyn (nemonoxacin) capsules in Taiwan

TaiGen Biotechnology Company, Limited ("TaiGen") today announced that together with its distribution partner, Holding Distribution, it has launched Taigexyn^® (nemonoxacin) capsules in Taiwan, the first market where Taigexyn^® is available. Taigexyn^® is a novel non-fluorinated quinolone antibiotic for the treatment of bacterial infections with both oral (capsule) and intravenous formulations. TaiGen successfully completed multiple clinical trials (Phase 1-3) of Taigexyn^® in community acquired pneumonia in Taiwan and mainland China and have filed for New Drug Application (NDA) of the oral formulation in both markets in March and April 2013 respectively. In December 2014, the Taiwan Food and Drug Administration approved the NDA and granted the new drug license for the oral formulation of Taigexyn^® to TaiGen. Taigexyn^® is out-licensed to Zhejiang Medicine in mainland China and to R-Pharm in Russia, Commonwealth Independent States, and Turkey.